explore -WSS

explore

author：hotspot 2025-09-06 04:30:42 - browse：396

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

hotspot

WSS

The painfully weak evidence on taking collagen to treat arthritis

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Lessons Learned: This is why you network to find that industry job you want

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

STAT reporters are Pulitzer Prize finalists for investigative reporting

Zapping the brain for stroke rehab: Pivotal clinical trial begins

knowledge

explore

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Cherokee Nation medical school graduates its first class

Dobbs anniversary: the lost opportunity of abortion as health care

Ohioans vote in high

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sage's campaign to raise awareness of postpartum depression hits a nerve

Jerome Adams on the need for new antivirals for Covid

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

BioMarin wins approval for gene therapy to treat hemophilia A

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

focus

‘The Bear’ and hospitality in hospitals

STAT reporters are Pulitzer Prize finalists for investigative reporting

Discs beat pads, tampons for heavy menstrual flow, new study shows

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Cherokee Nation medical school graduates its first class

Biden praises World Series champion Astros for impact off the field during White House celebration

hotspot

explore

explore

hotspot